# Tezepelumab COPD Exacerbation Study

> **NCT04039113** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 337 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **BIOLOGICAL:** Tezepelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04039113
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-30
- **Primary completion:** 2023-11-10
- **Final completion:** 2024-01-31
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2025-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04039113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04039113, "Tezepelumab COPD Exacerbation Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04039113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*